| GTO ID | GTC1799 |
| Trial ID | NCT03312205 |
| Disease | Leukemia | Lymphoma | Multiple Myeloma |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies |
| Year | 2017 |
| Country | China |
| Company sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Other ID(s) | daopeicart |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||